Pharming Group N.V. (PHAR) stock

PHARNasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 2, 2026Score 8/30

$12.60−0.35 (-2.70%)

Close on Nov 13, 2026Market cap $884.12MP/E 315.0Yield –

Pharming total debt

Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.

Pharming has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is PHAR.

Revenue growth26.6% · median 38.4%

Gross margin87.9% · median 87.4%

Operating margin6.9% · median -63.0%

Net margin0.8% · median -44.9%

Advertisement
300 × 250

See a number that looks wrong?